Vol 11, No 4 (2007)
Original paper
Published online: 2007-09-07
Hypotensive efficacy of eprosartan in postmenopausal women
Nadciśnienie tętnicze 2007;11(4):328-334.
Abstract
Background The aim of the study was to evaluate the efficacy
of eprosartan monotherapy treatment in postmenopausal
women with essential hypertension.
Material and methods 52 women with essential hypertension aged 52.8 ± 3.4 years who had last menstrual period 2 years ago. The women were not treated with any hypertensive medication for at least 1 month. Women received eprosartan (Teveten) 600 mg/daily between 6.30-7.00 am. Ambulatory blood pressure monitoring was performed with SpaceLabs 90207 before treatment, 6 and 12 weeks of therapy with eprosartan.
Results Twelve weeks of eprosartan treatment resulted in the lowest values of both SBP and DBP during day and night. After 6 weeks of eprosartan treatment in comparison with the period before treatment the significant reduction of systolic blood pressure (SBP) and diastolic blood pressure (DBP) during day and night was observed. During next 6 weeks further, statistically significant reduction of SBP only during day was observed. After 12 weeks of eprosartan treatment the lowest HT was also observed. The differences were statistically significant when compared to HT noted before treatment during day and night. The following 6 weeks of treatment showed statistically significant decreased values only during day.
Conclusions Eprosartan is an effective hypotensive monotherapy in postmenopausal women and showes more intensive hypotensive effects after 12 weeks of treatment with a stable dose than after 6 weeks of treatment. Eprosartan presents a good effect on the heart rate during day but especially during night.Arterial Hypertension 2007, vol. 11, no 4, pages 328-334.
Material and methods 52 women with essential hypertension aged 52.8 ± 3.4 years who had last menstrual period 2 years ago. The women were not treated with any hypertensive medication for at least 1 month. Women received eprosartan (Teveten) 600 mg/daily between 6.30-7.00 am. Ambulatory blood pressure monitoring was performed with SpaceLabs 90207 before treatment, 6 and 12 weeks of therapy with eprosartan.
Results Twelve weeks of eprosartan treatment resulted in the lowest values of both SBP and DBP during day and night. After 6 weeks of eprosartan treatment in comparison with the period before treatment the significant reduction of systolic blood pressure (SBP) and diastolic blood pressure (DBP) during day and night was observed. During next 6 weeks further, statistically significant reduction of SBP only during day was observed. After 12 weeks of eprosartan treatment the lowest HT was also observed. The differences were statistically significant when compared to HT noted before treatment during day and night. The following 6 weeks of treatment showed statistically significant decreased values only during day.
Conclusions Eprosartan is an effective hypotensive monotherapy in postmenopausal women and showes more intensive hypotensive effects after 12 weeks of treatment with a stable dose than after 6 weeks of treatment. Eprosartan presents a good effect on the heart rate during day but especially during night.Arterial Hypertension 2007, vol. 11, no 4, pages 328-334.
Keywords: eprosartanhypotensive efficacy24-hour ABPMwomen